Yuzhe Niu
Yuzhe Niu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro M. Mozzarelli
Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, New York
7 shared publications - Anatoly Urisman
Department of Pathology, University of California San Francisco, San Francisco, California
7 shared publications - Antonio Cuevas-Navarro
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA
7 shared publications - Charles M. Rudin
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
7 shared publications - Dmitri A. Petrov
Department of Biology, Stanford University, Stanford, CA 94305, USA
7 shared publications - Emily G. Shuldiner
Department of Biology, Stanford University, Stanford, California
7 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure S1 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Demographics of RIT1 mutant NSCLC
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure S1 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Demographics of RIT1 mutant NSCLC
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Table S1 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Table S1 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure S2 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Analysis of tumors and genes involved in RIT1 tumorigenesis
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure S2 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Analysis of tumors and genes involved in RIT1 tumorigenesis
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Data from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
RIT1 is a small GTPase of the RAS family, and RIT1 mutations have been identified in lung cancer, leukemia, and the developmental disorder Noonan syndrome. Mutations in RIT1 lead to increased protein levels due to impaired proteolysis, resulting in dysregulation of RAS/MAPK signaling and other pathways. In this study, we documented the diversity of RIT1 mutations in human lung cancer and showed that physiologic expression of RIT1 M90I is sufficient to drive autochthonous lung tumor development in vivo in mouse models. Evaluation of complementary methods to either inhibit RIT1 directly or the downstream RAS/MAPK pathway revealed that RIT1 M90I tumors are sensitive to SHP2 inhibitors and RAS nucleotide exchange inhibition. Additionally, a proof-of-concept chemical biology approach identified that RAS tri-complex inhibitors bind directly to GTP-bound RIT1, resulting in tumor shrinkage. These molecules provide a feasible therapeutic approach for RIT1-driven lung tumors.Significance:RIT1 is a bona fide oncogene that promotes lung tumorigenesis and can be directly targeted with RAS tri-complex inhibitors.See related commentary by Wu and Vaishnavi, p. 3186See related article by DiMarco et al., p. 3207
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
RIT1 is a small GTPase of the RAS family, and RIT1 mutations have been identified in lung cancer, leukemia, and the developmental disorder Noonan syndrome. Mutations in RIT1 lead to increased protein levels due to impaired proteolysis, resulting in dysregulation of RAS/MAPK signaling and other pathways. In this study, we documented the diversity of RIT1 mutations in human lung cancer and showed that physiologic expression of RIT1 M90I is sufficient to drive autochthonous lung tumor development in vivo in mouse models. Evaluation of complementary methods to either inhibit RIT1 directly or the downstream RAS/MAPK pathway revealed that RIT1 M90I tumors are sensitive to SHP2 inhibitors and RAS nucleotide exchange inhibition. Additionally, a proof-of-concept chemical biology approach identified that RAS tri-complex inhibitors bind directly to GTP-bound RIT1, resulting in tumor shrinkage. These molecules provide a feasible therapeutic approach for RIT1-driven lung tumors.Significance:RIT1 is a bona fide oncogene that promotes lung tumorigenesis and can be directly targeted with RAS tri-complex inhibitors.See related commentary by Wu and Vaishnavi, p. 3186See related article by DiMarco et al., p. 3207
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure S4 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Effect of RAS(ON) inhibitor in RIT1-driven models
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure S4 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Effect of RAS(ON) inhibitor in RIT1-driven models
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data Figure S3 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Effect of MAPK and RAS exchange inhibition in RIT1-driven models
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Figure S3 from RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
Effect of MAPK and RAS exchange inhibition in RIT1-driven models
- 11 July 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (17) , 3196-3206
RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
RIT1 is a small GTPase of the RAS family, and RIT1 mutations have been identified in lung cancer, leukemia, and the developmental disorder Noonan syndrome. Mutations in RIT1 lead to increased protein levels due to impaired proteolysis, resulting in dysregulation of RAS/MAPK signaling and other pathways. In this study, we documented the diversity of RIT1 mutations in human lung cancer and showed that physiologic expression of RIT1 M90I is sufficient to drive autochthonous lung tumor development in vivo in mouse models. Evaluation of complementary methods to either inhibit RIT1 directly or the downstream RAS/MAPK pathway revealed that RIT1 M90I tumors are sensitive to SHP2 inhibitors and RAS nucleotide exchange inhibition. Additionally, a proof-of-concept chemical biology approach identified that RAS tri-complex inhibitors bind directly to GTP-bound RIT1, resulting in tumor shrinkage. These molecules provide a feasible therapeutic approach for RIT1-driven lung tumors. Significance: RIT1 is a bona fide oncogene that promotes lung tumorigenesis and can be directly targeted with RAS tri-complex inhibitors. See related commentary by Wu and Vaishnavi, p. 3186 See related article by DiMarco et al., p. 3207
- 11 July 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (17) , 3196-3206
RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
RIT1 is a small GTPase of the RAS family, and RIT1 mutations have been identified in lung cancer, leukemia, and the developmental disorder Noonan syndrome. Mutations in RIT1 lead to increased protein levels due to impaired proteolysis, resulting in dysregulation of RAS/MAPK signaling and other pathways. In this study, we documented the diversity of RIT1 mutations in human lung cancer and showed that physiologic expression of RIT1 M90I is sufficient to drive autochthonous lung tumor development in vivo in mouse models. Evaluation of complementary methods to either inhibit RIT1 directly or the downstream RAS/MAPK pathway revealed that RIT1 M90I tumors are sensitive to SHP2 inhibitors and RAS nucleotide exchange inhibition. Additionally, a proof-of-concept chemical biology approach identified that RAS tri-complex inhibitors bind directly to GTP-bound RIT1, resulting in tumor shrinkage. These molecules provide a feasible therapeutic approach for RIT1-driven lung tumors. Significance: RIT1 is a bona fide oncogene that promotes lung tumorigenesis and can be directly targeted with RAS tri-complex inhibitors. See related commentary by Wu and Vaishnavi, p. 3186 See related article by DiMarco et al., p. 3207
- Open Access
- 6 May 2011
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 4 (1) , 21
Expression and distribution of PPP2R5C gene in leukemia
Background: Recently, we clarified at the molecular level novel chromosomal translocation t(14;14)(q11;q32) in a case of Sézary syndrome, which caused a rearrangement from TRAJ7 to the PPP2R5C gene. PPP2R5C is one of the regulatory B subunits of protein phosphatase 2A (PP2A). It plays a crucial role in cell proliferation, differentiation, and transformation. To characterize the expression and distribution of five different transcript variants of the PPP2R5C gene in leukemia, we analyzed the expression level of PPP2R5C in peripheral blood mononuclear cells from 77 patients with de novo leukemia, 26 patients with leukemia in complete remission (CR), and 20 healthy individuals by real-time PCR and identified the different variants of PPP2R5C by RT-PCR. Findings: Significantly higher expression of PPP2R5C was found in AML, CML, T-ALL, and B-CLL groups in comparison with healthy controls. High expression of PPP2R5C was detected in the B-ALL group; however, no significant difference was found compared with the healthy group. The expression level of PPP2R5C in the CML-CR group decreased significantly compared with that in the de novo CML group and was not significantly different from the level in the healthy group. By using different primer pairs that covered different exons, five transcript variants of PPP2R5C could be identified. All variants could be detected in healthy samples as well as in all the leukemia samples, and similar frequencies and distributions of PPP2R5C were indicated. Conclusions: Overexpression of PPP2R5C in T-cell malignancy as well as in myeloid leukemia cells might relate to its proliferation and differentiation. Investigation of the effect of target inhibition of this gene might be beneficial to further characterization of molecular mechanisms and targeted therapy in leukemia.
- 6 May 2011
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 4 (1) , 21
Open AccessExpression and distribution of PPP2R5C gene in leukemia
Background: Recently, we clarified at the molecular level novel chromosomal translocation t(14;14)(q11;q32) in a case of Sézary syndrome, which caused a rearrangement from TRAJ7 to the PPP2R5C gene. PPP2R5C is one of the regulatory B subunits of protein phosphatase 2A (PP2A). It plays a crucial role in cell proliferation, differentiation, and transformation. To characterize the expression and distribution of five different transcript variants of the PPP2R5C gene in leukemia, we analyzed the expression level of PPP2R5C in peripheral blood mononuclear cells from 77 patients with de novo leukemia, 26 patients with leukemia in complete remission (CR), and 20 healthy individuals by real-time PCR and identified the different variants of PPP2R5C by RT-PCR. Findings: Significantly higher expression of PPP2R5C was found in AML, CML, T-ALL, and B-CLL groups in comparison with healthy controls. High expression of PPP2R5C was detected in the B-ALL group; however, no significant difference was found compared with the healthy group. The expression level of PPP2R5C in the CML-CR group decreased significantly compared with that in the de novo CML group and was not significantly different from the level in the healthy group. By using different primer pairs that covered different exons, five transcript variants of PPP2R5C could be identified. All variants could be detected in healthy samples as well as in all the leukemia samples, and similar frequencies and distributions of PPP2R5C were indicated. Conclusions: Overexpression of PPP2R5C in T-cell malignancy as well as in myeloid leukemia cells might relate to its proliferation and differentiation. Investigation of the effect of target inhibition of this gene might be beneficial to further characterization of molecular mechanisms and targeted therapy in leukemia.